Citation

Leo J. Ethical. Hum. Sci. Serv. 2004; 6(2): 147-151.

Copyright

(Copyright © 2004, Springer Publishing)

DOI

unavailable

PMID

unavailable

Abstract

In response to the growing media awareness of the potential link between SSRIs and increased thoughts of suicide in children, The American College of Neuropsycho pharmacology (ACNP) recently released an executive summary from its task force assigned to investigate this question (ACNP, 2004). Their Executive Summary, released just days before the FDA hearing on this issue, explains that there is no link between SSRIs and suicide, yet they ignore the work of David Healy, the most recent critic of the flawed methodology of the clinical trials investigation. The ANCP's summary essentially provides a framework for how the FDA should not proceed with its own investigation. The following article is a response to the ANCP.

Language: en

Keywords

human; child; depression; suicidal behavior; ethics; review; fluoxetine; paroxetine; serotonin uptake inhibitor; sertraline; priority journal; mental health service; psychopharmacology; placebo; food and drug administration; medical society